None
DE
Barrington Research Reiterates “Outperform” Rating for Anika Therapeutics (NASDAQ:ANIK)
['Max Byerly']
Ticker Report
Anika Therapeutics (NASDAQ:ANIK – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at Barrington Research in a report issued on Tuesday,Benzinga reports.
Anika Therapeutics Stock Down 0.7%NASDAQ ANIK traded down $0.07 during trading hours on Tuesday, hitting $9.27.
Anika Therapeutics has a twelve month low of $7.87 and a twelve month high of $25.65.
Get Anika Therapeutics alerts:Institutional Trading of Anika TherapeuticsHedge funds and other institutional investors have recently modified their holdings of the business.
Further ReadingReceive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
['outperform'
'shares'
'stock'
'rating'
'quarter'
'reiterates'
'therapeutics'
'barrington'
'anika'
'research'
'companys'
'biotechnology'
'additional'
'nasdaqanik'
'financial'
'owns']